Four Human Thiopurine S-Methyltransferase Alleles Severely Affect Protein Structure and Dynamics

Journal of Molecular Biology

Volumn 379, Issue 4, 2008, Pages 803-814

  Rutherford, Karen ^a   Daggett, Valerie ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b University of Washington   (United States)

Author keywords

molecular dynamics; pharmacogenetics; polymorphisms; protein structure; thiopurine S methyltransferase

Indexed keywords

THIOPURINE METHYLTRANSFERASE; THREONINE;

ARTICLE; BINDING SITE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 44149113487     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.04.032     Document Type: Article

References (46)

1. J.F. Deeken W.D. Figg S.E. Bates A. Sparreboom Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics Anticancer Drugs 18 2007 111 126
2. E. Schaeffeler M. Stanulla J. Greil M. Schrappe M. Eichelbaum U.M. Zanger M. Schwab A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL Leukemia 17 2003 1422 1424
3. M. Stanulla E. Schaeffeler T. Flohr G. Cario A. Schrauder M. Zimmermann Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia JAMA 293 2005 1485 1489
4. H.L. McLeod S. Coulthard A.E. Thomas S.C. Pritchard D.J. King S.M. Richards Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia Br. J. Haematol. 105 1999 696 700
5. I.M. Hisamuddin M.A. Wehbi V.W. Yang Pharmacogenetics and diseases of the colon Curr. Opin. Gastroenterol. 23 2007 60 66
6. J.W. Winter D. Gaffney D. Shapiro R.J. Spooner A.M. Marinaki J.D. Sanderson P.R. Mills Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 25 2007 1069 1077
7. S. Haglund M. Lindqvist S. Almer C. Peterson J. Taipalensuu Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease Clin. Chem. 50 2004 288 295
8. M. Lindqvist K. Skoglund A. Karlgren P. Soderkvist C. Peterson I. Kidhall S. Almer Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23 Pharmacogenet. Genomics 17 2007 891 895
9. J.F. Colombel N. Ferrari H. Debuysere P. Marteau J.P. Gendre B. Bonaz Genotypic analysis of thiopurine S -methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
10. E.M. Frohman E. Havrdova B. Levinson O. Slanar Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms Mult. Scler. 12 2006 108 111
11. S. Coulthard L. Hogarth The thiopurines: an update Invest. New Drugs 23 2005 523 532
12. E.Y. Krynetski J.D. Schuetz A.J. Galpin C.H. Pui M.V. Relling W.E. Evans A single point mutation leading to loss of catalytic activity in human thiopurine S -methyltransferase Proc. Natl Acad. Sci. USA 92 1995 949 953
13. T. Loennechen C.R. Yates M.Y. Fessing M.V. Relling E.Y. Krynetski W.E. Evans Isolation of a human thiopurine S -methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans Clin. Pharmacol. Ther. 64 1998 46 51
14. O.E. Salavaggione L. Wang M. Wiepert V.C. Yee R.M. Weinshilboum Thiopurine S -methyltransferase pharmacogenetics: variant allele functional and comparative genomics Pharmacogenet. Genomics 15 2005 801 815
15. Y.Y. Hon M.Y. Fessing C.H. Pui M.V. Relling E.Y. Krynetski W.E. Evans Polymorphism of the thiopurine S -methyltransferase gene in African-Americans Hum. Mol. Genet. 8 1999 371 376
16. E. Schaeffeler M. Eichelbaum W. Reinisch U.M. Zanger M. Schwab Three novel thiopurine S -methyltransferase allelic variants (TPMT*20, *21, *22)—association with decreased enzyme function Hum. Mutat. 27 2006 976
17. M. Lindqvist S. Haglund S. Almer C. Peterson J. Taipalensu E. Hertervig Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity Pharmacogenetics 14 2004 261 265
18. E. Schaeffeler C. Fischer D. Brockmeier D. Wernet K. Moerike M. Eichelbaum Comprehensive analysis of thiopurine S -methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Pharmacogenetics 14 2004 407 417
19. L. Wang R. Weinshilboum Thiopurine S -methyltransferase pharmacogenetics: insights, challenges and future directions Oncogene 25 2006 1629 1638
20. T. Sasaki E. Goto Y. Konno M. Hiratsuka M. Mizugaki Three novel single nucleotide polymorphisms of the human thiopurine S -methyltransferase gene in Japanese individuals Drug Metab. Pharmacokinet. 21 2006 332 336
21. E.Y. Krynetski W.E. Evans Genetic polymorphism of thiopurine S -methyltransferase: molecular mechanisms and clinical importance Pharmacology 61 2000 136 146
22. E.Y. Krynetski W.E. Evans Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S -methyltransferase paradigm Pharm. Res. 16 1999 342 349
23. S.A. Coulthard E.C. Matheson A.G. Hall L.A. Hogarth The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment Nucleosides Nucleotides Nucleic Acids 23 2004 1385 1391
24. B. Wusk G.A. Kullak-Ublick C. Rammert A. von Eckardstein M. Fried K.M. Rentsch Thiopurine S -methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs Eur. J. Clin. Pharmacol. 60 2004 5 10
25. H.L. Tai E.Y. Krynetski C.R. Yates T. Loennechen M.Y. Fessing N.F. Krynetskaia W.E. Evans Thiopurine S -methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians Am. J. Hum. Genet. 58 1996 694 702
26. H.L. Tai E.Y. Krynetski E.G. Schuetz Y. Yanishevski W.E. Evans Enhanced proteolysis of thiopurine S -methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity Proc. Natl Acad. Sci. USA 94 1997 6444 6449
27. L. Wang T.V. Nguyen R.W. McLaughlin L.A. Sikkink M. Ramirez-Alvarado R.M. Weinshilboum Human thiopurine S -methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation Proc. Natl Acad. Sci. USA 102 2005 9394 9399
28. L. Wang W. Sullivan D. Toft R. Weinshilboum Thiopurine S -methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation Pharmacogenetics 13 2003 555 564
29. H.L. Tai M.Y. Fessing E.J. Bonten Y. Yanishevsky A. d'Azzo E.Y. Krynetski W.E. Evans Enhanced proteasomal degradation of mutant human thiopurine S -methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C Pharmacogenetics 9 1999 641 650
30. H. Wu J.R. Horton K. Battaile A. Allali-Hassani F. Martin H. Zeng Structural basis of allele variation of human thiopurine- S -methyltransferase Proteins 67 2007 198 208
31. A.J. Shield B.A. Thomae B.W. Eckloff E.D. Wieben R.M. Weinshilboum Human catechol O -methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes Mol. Psychiatry 9 2004 151 160
32. Rutherford, K., Alphandéry, E., McMillan, A., Daggett, V. & Parson W. W. (2008). The V108M mutation decreases the structural stability of catechol O-methyltransferase. Biochim. Biophys. Acta . In press.
33. N.J. Cotton B. Stoddard W.W. Parson Oxidative inhibition of human soluble catechol- O -methyltransferase J. Biol. Chem. 279 2004 23710 23718
34. T. Lotta J. Vidgren C. Tilgmann I. Ulmanen K. Melen I. Julkunen J. Taskinen Kinetics of human soluble and membrane-bound catechol O -methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme Biochemistry 34 1995 4202 4210
35. K. Rutherford B.J. Bennion W.W. Parson V. Daggett The 108M polymorph of human catechol O -methyltransferase is prone to deformation at physiological temperatures Biochemistry 45 2006 2178 2188
36. C. Lee M.P. Schwartz S. Prakash M. Iwakura A. Matouschek ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal Mol. Cell 7 2001 627 637
37. A. Matouschek Protein unfolding—an important process in vivo ? Curr. Opin. Struct. Biol. 13 2003 98 109
38. M. Levitt ENCAD, Energy Calculations and Dynamics 1990 Molecular Applications Group Palo Alto, CA
39. D.A.C. Beck D.O.V. Alonso V. Daggett il mm, in lucem Molecular Mechanics 2000–2008 University of Washington Seattle, WA
40. D.A. Beck V. Daggett Methods for molecular dynamics simulations of protein folding/unfolding in solution Methods 34 2004 112 120
41. M. Levitt M. Hirshberg R. Sharon V. Daggett Potential energy function and parameters for simulations of the molecular dynamics of proteins and nucleic acids in solution Comput. Phys. Commun. 91 1995 215 231
42. M. Levitt M. Hirshberg R. Sharon K.E. Laidig V. Daggett Calibration and testing of a water model for simulation of the molecular dynamics of proteins and nucleic acids in solution J. Phys. Chem. B 101 1997 5051 5061
43. G.S. Kell Precise representation of volume properties of water at one atmosphere J. Chem. Eng. Data 12 1967 66 69
44. D.A. Beck R.S. Armen V. Daggett Cutoff size need not strongly influence molecular dynamics results for solvated polypeptides Biochemistry 44 2005 609 616
45. S.J. Hubbard J.M. Thorton NACCESS 1993 Department of Biochemistry and Molecular Biology, University College London
46. E.F. Pettersen T.D. Goddard C.C. Huang G.S. Couch D.M. Greenblatt E.C. Meng T.E. Ferrin UCSF Chimera—a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612